Search

Your search keyword '"Girard PM"' showing total 505 results

Search Constraints

Start Over You searched for: Author "Girard PM" Remove constraint Author: "Girard PM"
505 results on '"Girard PM"'

Search Results

1. Molecular epidemiology of ESBL-producing E. coli and K. pneumoniae: establishing virulence clusters

2. Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study

3. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial

4. Efficacy, safety and patient‐reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor‐experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study)

5. Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

6. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

9. Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D study

12. Efficacy, safety and patient‐reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor‐experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study)

13. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study

14. Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors

15. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial

16. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa

17. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

18. Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial

19. Pneumocystisjiroveciidihydropteroate synthase genotypes in French patients with pneumocystosis: a 1998–2001 prospective study

20. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are created equal

22. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy

23. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study

24. History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change

25. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study

26. Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe

27. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome

28. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients

29. Dialysis and renal transplantation in HIV-infected patients: a European survey

30. Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe

31. Telaprevir combination therapy in HCV/HIV co-infected patients (INSIGHT study): sustained virologic response at 12 weeks final analysis

32. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?

33. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies

34. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction

35. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

36. Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial.

37. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART Study

39. The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach

43. Schistosoma Mansoni Infection and Liver Graft

48. Factors Associated With Virological Failure in HIV-1-Infected Patients Receiving Darunavir/Ritonavir Monotherapy.

50. Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption.

Catalog

Books, media, physical & digital resources